Zynex Inc PEG
What is the PEG of Zynex Inc?
The PEG of Zynex Inc is N/A
What is the definition of PEG?
Price/earnings to growth (PEG) ratio is a stock’s P/E ratio divided by a predicted growth rate of its earnings for a time period of 5 years.
= forward PE / 5-year EPS growth rate
The PEG ratio is calculated by dividing the P/E ratio by the company's expected earnings growth rate in the next 5 years. Since using just the P/E ratio would make high-growth companies appear overvalued relative to others, the PEG ratio is considered to be a convenient approximation. PEG is a widely employed indicator of a stock's possible true value.
Similar to P/E ratios, a lower PEG means that the stock is undervalued more. It is favored by many over the price/earnings ratio because it also accounts for growth. The PEG ratio of 1 is sometimes said to represent a fair trade-off between the values of cost and the values of growth, indicating that a stock is reasonably valued given the expected growth. A crude analysis suggests that companies with PEG values between 0 and 1 may provide higher returns. A PEG Ratio can also be a negative number if a stock's present income figure is negative, (negative earnings) or if future earnings are expected to drop (negative growth). PEG ratios calculated from negative present earnings are viewed with skepticism as almost meaningless, other than as an indication of high investment risk.
What does Zynex Inc do?
zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.